DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • September 18th, 2017 • Immunomedics Inc • In vitro & in vivo diagnostic substances • Delaware
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is executed as of February 10, 2017 (the “Execution Date”), by and between IMMUNOMEDICS, INC., a Delaware corporation having its principal place of business at 300 The American Road, Morris Plains, New Jersey 07950 (“Company”), and SEATTLE GENETICS, INC., a Delaware corporation, having a place of business at 21823 30th Drive SE, Bothell, Washington 98021 (“Licensee”). Company and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
